SecBot SecBot
PRESS-RELEASE ·Filed Sep 1, 2026

MDT

Medtronic plc
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The guidance raise and broad-based strength across all segments confirm durable momentum. Traders should watch for continued execution on new growth platforms (Cardiac Ablation, Affera, Altaviva, Cornerstone Robotics) and the Diabetes separation timeline. The extra fiscal week contributed ~$570M to Q1 organic growth, so Q2 comps will be tougher, monitor for sequential deceleration.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$92.04
T+0 close · Sep 1, 2026 · via day close
Latest settled
−5.21%
T+20 · $87.25 · next T+60 in 8d
Vs SPY
−6.39%
α at T+20
Latest observation
+12.24%
T+52 · FF3 residual α
  1. T+0 · Sep 1 $92.04entry
  2. T+1 · 3mo ago +0.15%α −0.29% · $92.18
  3. T+5 · 2mo ago −0.16%α −0.24% · $91.89
  4. T+20 · 7w ago −5.21%α −6.39% · $87.25
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Medtronic reported Q1 FY27 revenue of $9.756B (+13.7% organic, ~200bps above guidance midpoint) and non-GAAP EPS of $1.45, ahead of consensus. The company raised FY27 organic revenue growth guidance to 7.25%-7.75% (from 6.75%-7.25%) and EPS guidance to $5.94-$6.00. Broad-based strength across Cardiovascular (+18.9% organic), Neuroscience (+9.3%), Medical Surgical (+10.2%), and Diabetes (+14.9%) drove the beat, signaling durable momentum despite the extra fiscal week contributing ~$570M to organic growth.

Key Financial Metrics

EPS
$1.45
est $1.39 · +4.3%
Revenue
$9.8B
est $9.5B · +2.3% · +13.7% YoY
Rating
strong beat
Guidance
7.25% to 7.75% organic growth
raised
Free Cash Flow
$1.3B
Gross Margin
65%

Key Facts

  • Revenue of $9.756B beat consensus of $9.54B by ~2.3%
  • Non-GAAP EPS of $1.45 beat consensus of $1.39 by ~4.3%
  • Raised FY27 organic revenue growth guidance to 7.25%-7.75% from 6.75%-7.25%
  • Raised FY27 non-GAAP EPS guidance to $5.94-$6.00 from $5.90-$6.00
  • Cardiovascular portfolio grew 18.9% organic, led by Electrophysiology Therapies (+29.1%)
  • Diabetes revenue grew 14.9% organic to $843M
  • Free cash flow of $1.290B vs $584M in prior year quarter
  • GAAP diluted EPS of $1.14 vs $0.81 in prior year quarter

Financial Impact

Revenue beat consensus by ~$216M; EPS beat by $0.06; guidance raised 50bps on organic growth and $0.04-$0.00 on EPS midpoint

revenueepsguidanceorganic growth

Risk Factors

  • Extra fiscal week (~$570M) inflated Q1 organic growth, creating a tough comp for Q2
  • Diabetes separation structure (split-off vs spin-off) remains undecided, creating uncertainty
  • Restructuring charges ($72M) and acquisition costs continue to weigh on GAAP profitability

Market Snapshot

Exchange
NYSE
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
65% bullish (34 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302865648

Track record

53 reports on MDT

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +15.30% at T+60 after the Jun 3, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $101.59 Now $102.88 +1.27% settles Feb 8
  3. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $98.88 Now $102.88 +4.05% settles Feb 1
  4. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $94.63 Now $102.88 +8.72% settles Jan 15
  5. Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
  6. Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
  7. Oct 15, 20264w ago 144 Neutral 3/10 Entry $95.45 Now $102.88 +7.78% settles Jan 12
  8. Oct 14, 20264w ago SC TO-I/A Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
  9. Oct 14, 20264w ago 425 Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
  10. Oct 13, 20264w ago SC TO-I/A Neutral 5/10 Entry $93.01 Now $102.88 +10.61% settles Jan 8
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (11h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026